Drug intelligence / Profile preview

19-O-triphenylmethylandrographolide

Development stage: Preclinical
Lead developer: Mahidol University
Modality: Small Molecules
Administration: Intravenous

Overview

RSPP050 (19-O-triphenylmethylandrographolide) is a semi-synthetic diterpenoid lactone analogue of andrographolide, a natural compound derived from *Andrographis paniculata*. It is being investigated for its anticancer properties, particularly in the treatment of hepatocellular carcinoma. Research has focused on enhancing its delivery and imaging capabilities using galactose-targeted micelles that encapsulate both RSPP050 and superparamagnetic iron oxide (SPIO) nanoparticles. This theranostic approach aims to improve tumor targeting via the asialoglycoprotein receptor on HepG2 cells while enabling T2*-weighted MRI monitoring of drug uptake and therapeutic efficacy.

Other names: 19-O-triphenylmethylandrographolide

Beyond the preview

Go deeper on 19-O-triphenylmethylandrographolide.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 19-O-triphenylmethylandrographolide.

Explore the full profile